Comparsion Of Therapic Efficiency And Cardiotoxicity Of PLD And Pirarubicin In The Neoadjuvent Chemotherapy Of Breast Cancer

Aim:we conductedthisstudytoexplorethedifferencein therapeutic effect and cardiac toxicity in the neoadjuvant chemotherapy of breast cancer betweenPLD andtraditional anthracycline drugs.Method:Data was collected from breast cancer patients who were diagnosed pathologically and received neoadjuvant chemotherapy between 9/2016 and 10/2017.Patients who were given PLD defined as study group and based on the clinico-pathological characteristic such as patients age,gender,ECOG score,pathological and molecular tumor type,clinical tumor stage,1:1 pairing control group patients were extracted from anthracycline group.Variation of Clinical tumor changes,pathological changes before and after surgery,cardiac function changes and side effects of two groups of drugs was analyzed to evaluate the therapeutic effect and cardiac toxicity of two drugs.Result:A total of 20 patients enrolled in the study group and control group respectively.There was no significant difference between the two groups in the average age,ECOG score,amenorrhea,tumor staging,molecular typing,and cardiac risk factors(p < 0.05).In the study group,17 patients(85%)completed the original chemotherapy regimens,and the in the control group all of the patients completed the chemotherapy regimens as planed.In the Postoperative pathological evaluation,pCR rate of the study group was 20%(4/20),and 10%(2/20)in the control group,there was no statistical difference in two groups.In the clinical evolution,the number of patients who achieve cCR,cPR,SD,PD were respectively 1,13,5,1,and the numbers were 0,17,3,0 in the control group,and similarly no statistical difference was founded between two groups.According to Postoperative pathological Miller-Payne(MP)classification,there were 0,6,7,3 and 4 patients in the doxorubicin group and 0 ? 4 ? 9 ? 5 ? 2 patients in the anthracycline group,defined as MP?,MP?,MP? and MP? respectively,and no statistical difference was founded between two groups.The control group and the study group did not have the cardiotoxicity event as defined in the experiment.However,three of the patients who were treated with pirarubicin has find cardiac discomfort and transferred to the study group.II-IV degree of bone marrow suppression rate was 20% in both the study group and control group.II-IV degree of Sibling syndrome rate was 25% in the study group and 5% in the control group.II-IV degree of Nausea and vomiting event was happened 15% of patients in the control group and 10% of patients in study group.Alopecia rate was 85% in the control group and 90% in the study group.Conclusion:PLD and pirarubicin have the same therapeutic effect in the neoadjuvant chemotherapy of breast cancer.PLD have the same cardiac toxicity withpirarubicin,but have more Skin toxicity rather than pirarubicin.